2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE

January 20 | 2025

2cureX has appointed Mangold Fondkommission AB (“Mangold”) as the Company’s liquidity provider.

Mangold will continuously place trading items on both bid and ask side in the order book for the 2cureX share and ensure that a predetermined spread is maintained in the share. The purpose of the liquidity providing is to promote good liquidity and ensure a low spread between the bid and ask price in current trading. The assignment commenced 20 January 2025.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.se

Certified Adviser: Redeye AB